Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Keck School of Medicine of USC

Neither a doctor nor a teaching hospital

Research payments

$976,090

107 payments

Through program year 2025, Keck School of Medicine of USC is reported as receiving $976,090 in research payments, across 107 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $252,086 21
2024 Research $232,112 33
2023 Research $231,255 4
2022 Research $55,022 5
2021 Research $1,550 2
2020 Research $13,115 5
2019 Research $190,950 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. PharmaEssentia USA Corporation $298,259 34 payments
  2. Merck Sharp & Dohme Corporation $243,296 2 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $233,467 2 payments
  4. Astellas Pharma Global Development $75,714 5 payments
  5. Pfizer Inc. $40,795 2 payments
  6. Bolton Medical Inc $31,622 6 payments
  7. Ge Healthcare $22,181 7 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $15,774 5 payments
  9. Imperative Care, INc $10,603 5 payments
  10. GlaxoSmithKline, LLC. $2,056 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. BI 905677 phase I first in man dose finding study $233,467 2 payments
  2. A22-301 $197,042 20 payments
  3. A Phase IIa trial of sEphB4-HSA in combination with Anti PD-L1 Antibody Pembrolizumab, MK-7435 in patients with non-small cell lung and head,neck cancer $162,197 1 payment
  4. A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2bnjft(P1101) in Adult Patients with Essential Thrombocythemia $101,217 14 payments
  5. A Phase IIa trial of sEphB4-HSA in combination with Anti PD-L1 Antibody (Pembrolizumab, MK-7435) in patients with non-small cell lung and head/neck cancer $81,099 1 payment
  6. A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4 $69,339 2 payments
  7. A Phase 1B2 Open Label Umbrella Study of Sasanlimab Combined With Anticancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Nonsmall Cell Lung Cancer Nsclc $39,895 1 payment
  8. Extend $29,437 5 payments
  9. Impact of Cerianna PET/CT on Treatment Decisions in Metastatic Breast Cancer Patients $22,181 7 payments
  10. A multicenter Phase 1 study to evaluate the safety tolerability pharmacokinetics and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive locally advanced or metastatic solid tumors $12,062 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record